This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Astellas Pharma (ALPMF) Receives a Hold from Mizuho Securities
In a report released today, from Mizuho Securities maintained a Hold rating on Astellas Pharma, with a price target of Yen2,500.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Astellas Pharma has an analyst consensus of Hold, with a price target consensus of Yen2,296.35.
ALPMF market cap is currently Yen4405.6B and has a P/E ratio of 9.34.
Read More on ALPMF:
Disclaimer & DisclosureReport an Issue
- Astellas and HOVON Phase 3 AML Trial for Xospata Misses Survival Goal
- Astellas Flags Risks and Uncertainties Around Sustainability Plans and Pipeline
- Why Is Vir Biotechnology Stock Up Today?
- Astellas Settles Myrbetriq Patent Disputes with Lupin and Zydus
- Astellas-Backed Bladder Cancer Trial Nears Key Data Moment After Study Completion
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
